Market news

EHC is expanding near Houston with its first small-format rehab hospital and a 60-bed replacement facility in The Woodlands.

Encompass Health (EHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Detailed price information for Encompass Health Corp (EHC-N) from The Globe and Mail including charting and trades.

Encompass Health (EHC) said Tuesday it opened a 50-bed inpatient rehabilitation hospital in Lower Pr

On August 5, Encompass Health (NYSE:EHC) reported second quarter results that beat its own expectations by enough to raise full year guidance twice in the same release, first on revenue and then on profit. Net operating revenue climbed 9.6% to $1.597 billion, and adjusted earnings per share rose 10.7% to $1.55. For the largest owner […]

Andrew L Price, Chief Accounting Officer, on August 31, 2026, sold 5,211 shares in Encompass Health

Encompass Health is rated a Buy due to its compelling growth prospects, operational excellence, and strong position. Read more on EHC stock here.

Encompass Health (EHC) has put a fresh financing framework in place, filing an omnibus shelf registration that covers potential future offerings of common and preferred stock, warrants and debt securities. See our latest analysis for Encompass Health. Encompass Health shares have eased in the past week following the shelf registration and recent $100 million senior notes issuance, although a 30 day share price return of 6.57% and a 3 year total shareholder return of 77.79% indicate momentum...

Encompass Health is back in focus as analysts edge their price targets higher, with fair value estimates moving from about US$145.25 to roughly US$148.17. Much of this shift traces to recent Q2 results, updated 2026 guidance, and a wave of research that now clusters price targets in the US$144 to US$150 range. As you read on, you will see what is driving these revisions and how to track the next moves in the Encompass Health story. Stay updated as the Fair Value for Encompass Health shifts by...

EHC's rising demand, higher patient acuity and hospital expansion support growth, while rising expenses and debt remain key risks.

This sale reduced an insider's direct common stock position by 27%, though a majority of the position remains held through trusts and spousal holdings.

This sale reduced an insider's direct equity holdings by 11%.

Detailed price information for Encompass Health Corp (EHC-N) from The Globe and Mail including charting and trades.

Encompass Health’s second quarter reflected robust demand for inpatient rehabilitation, with the company delivering revenue growth above Wall Street expectations and a double-digit gain in non-GAAP earnings per share. Management attributed the strong results to ongoing investments in clinical workforce development and capacity additions, as well as continued momentum in treating higher-acuity patient categories like stroke and brain injury. CEO Mark Tarr highlighted that the company’s patient ou

5 Revealing Analyst Questions From Encompass Health’s Q2 Earnings Call

Douglas E Coltharp, Executive Vice President & Chief Financial Officer, on August 10, 2026, sold 18,

Detailed price information for Encompass Health Corp (EHC-N) from The Globe and Mail including charting and trades.

Detailed price information for Encompass Health Corp (EHC-N) from The Globe and Mail including charting and trades.

Detailed price information for Encompass Health Corp (EHC-N) from The Globe and Mail including charting and trades.

Detailed price information for Encompass Health Corp (EHC-N) from The Globe and Mail including charting and trades.

Moby summary of Encompass Health Corporation's Q2 2026 earnings call

The headline numbers for Encompass Health (EHC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Encompass Health (EHC) delivered earnings and revenue surprises of +4.73% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Health care services provider Encompass Health (NYSE:EHC) announced better-than-expected revenue in Q2 CY2026, with sales up 9.6% year on year to $1.60 billion. The company expects the full year’s revenue to be around $6.45 billion, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was 4.7% above analysts’ consensus estimates.